Clinical symptoms of SARS‐CoV‐2 breakthrough infection during the Omicron period in relation to baseline immune status and booster vaccination—A prospective multicentre cohort of health professionals (SURPRISE study)
暂无分享,去创建一个
L. Risch | P. Vernazza | M. Schlegel | S. Güsewell | P. Rieder | S. Kuster | C. Kahlert | P. Kohler | D. Vuichard-Gysin | A. Friedl | B. Wiggli | A. McGeer | A. Brucher | M. Ruetti | R. Stocker | U. Besold | H. Schmid | E. Lemmenmeier | J. C. Möller | T. Egger | D. Meier Kleeb | B. Babouee Flury | Onicio Leal | Manuela Ortner | Oliver Speer | Baharak Babouee Flury
[1] L. Risch,et al. Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland—A multicentre cohort study , 2022, PLoS medicine.
[2] S. Ladhani,et al. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021–March, 2022: a national, observational, test-negative, case-control study , 2022, The Lancet Infectious Diseases.
[3] Gheyath K Nasrallah,et al. Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections , 2022, The New England journal of medicine.
[4] N. Pearce,et al. Vaccination plus previous infection: protection during the omicron wave in Brazil , 2022, The Lancet Infectious Diseases.
[5] N. Courtejoie,et al. Vaccine-induced and naturally-acquired protection against Omicron and Delta symptomatic infection and severe COVID-19 outcomes, France, December 2021 to January 2022 , 2022, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[6] E. Theel,et al. Immunity to SARS-CoV-2: What Do We Know and Should We Be Testing for It? , 2022, Journal of clinical microbiology.
[7] S. Gharbia,et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant , 2022, The New England journal of medicine.
[8] L. Risch,et al. Symptoms compatible with long-COVID in healthcare workers with and without SARS-CoV-2 infection - results of a prospective multicenter cohort , 2021, medRxiv.
[9] L. Risch,et al. Impact of baseline SARS-CoV-2 antibody status on syndromic surveillance and the risk of subsequent COVID-19—a prospective multicenter cohort study , 2021, BMC Medicine.
[10] L. Risch,et al. Non-occupational and occupational factors associated with specific SARS-CoV-2 antibodies among hospital workers – A multicentre cross-sectional study , 2020, Clinical Microbiology and Infection.